NU 670 FINAL EXAM QUESTIONS WITH
CORRECT ANSWERS
Pharmacokinetics ||(PK) ||- ||CORRECT ||ANSWER✔✔-What ||the ||body ||does ||to ||the ||drug; ||ADME ||
(absorption, ||distribution, ||metabolism, ||excretion)
ADME ||- ||CORRECT ||ANSWER✔✔-A: ||absorption; ||D: ||distribution; ||M: ||metabolism; ||E: ||
excretion
Pharmacodynamics ||(PD) ||- ||CORRECT ||ANSWER✔✔-What ||the ||drug ||does ||to ||the ||body; ||
receptor ||binding ||effects
Agonist ||- ||CORRECT ||ANSWER✔✔-Binds ||+ ||activates ||receptor ||→ ||full ||response
Partial ||agonist ||- ||CORRECT ||ANSWER✔✔-Binds ||+ ||activates ||receptor ||→ ||smaller ||response ||
than ||full ||agonist
Inverse ||agonist ||- ||CORRECT ||ANSWER✔✔-Binds ||+ ||produces ||opposite ||effect ||of ||agonist ||
(reduces ||baseline ||receptor ||activity)
Antagonist ||- ||CORRECT ||ANSWER✔✔-Binds ||receptor ||but ||blocks ||activation ||(no ||intrinsic ||
activity)
Inducers ||effect ||on ||drug ||levels ||- ||CORRECT ||ANSWER✔✔-↑ ||metabolism ||→ ||↓ ||drug ||level ||
→ ||↓ ||efficacy
, Inhibitors ||effect ||on ||drug ||levels ||- ||CORRECT ||ANSWER✔✔-↓ ||metabolism ||→ ||↑ ||drug ||level ||
→ ||↑ ||toxicity ||risk
Excitatory ||neurotransmitter ||(main) ||- ||CORRECT ||ANSWER✔✔-Glutamate
Inhibitory ||neurotransmitter ||(main) ||- ||CORRECT ||ANSWER✔✔-GABA
CYP ||interaction ||risk ||w/ ||fluoxetine ||+ ||inhibitor ||- ||CORRECT ||ANSWER✔✔-↑ ||SSRI ||levels ||→ ||
↑ ||serotonin ||syndrome ||risk ||(ex: ||ketoconazole)
Sample ||Q: ||Fluoxetine ||+ ||ketoconazole ||risk? ||- ||CORRECT ||ANSWER✔✔-CYP ||inhibitor ||
increases ||SSRI ||level ||→ ||↑ ||serotonin ||syndrome ||risk
MDD ||(DSM-5-TR) ||core ||criteria ||- ||CORRECT ||ANSWER✔✔-≥5 ||symptoms ||for ||≥2 ||weeks; ||one ||
must ||be ||depressed ||mood ||OR ||anhedonia
Persistent ||Depressive ||Disorder ||duration ||- ||CORRECT ||ANSWER✔✔-≥2 ||years ||of ||depressed ||
mood ||+ ||≥2 ||other ||symptoms
PMDD ||- ||CORRECT ||ANSWER✔✔-Diagnosed ||as ||Premenstrual ||Dysphoric ||Disorder
SSRIs ||first-line ||for ||- ||CORRECT ||ANSWER✔✔-MDD ||(and ||commonly ||anxiety ||disorders)
MAOI ||key ||safety ||issue ||- ||CORRECT ||ANSWER✔✔-Hypertensive ||crisis ||with ||tyramine-
containing ||foods
MAOI ||washout ||rule ||- ||CORRECT ||ANSWER✔✔-WaIt ||2 ||weeks ||before ||starting ||SSRIs ||after ||
MAOI ||(and ||vice ||versa ||per ||clinician ||plan)
CORRECT ANSWERS
Pharmacokinetics ||(PK) ||- ||CORRECT ||ANSWER✔✔-What ||the ||body ||does ||to ||the ||drug; ||ADME ||
(absorption, ||distribution, ||metabolism, ||excretion)
ADME ||- ||CORRECT ||ANSWER✔✔-A: ||absorption; ||D: ||distribution; ||M: ||metabolism; ||E: ||
excretion
Pharmacodynamics ||(PD) ||- ||CORRECT ||ANSWER✔✔-What ||the ||drug ||does ||to ||the ||body; ||
receptor ||binding ||effects
Agonist ||- ||CORRECT ||ANSWER✔✔-Binds ||+ ||activates ||receptor ||→ ||full ||response
Partial ||agonist ||- ||CORRECT ||ANSWER✔✔-Binds ||+ ||activates ||receptor ||→ ||smaller ||response ||
than ||full ||agonist
Inverse ||agonist ||- ||CORRECT ||ANSWER✔✔-Binds ||+ ||produces ||opposite ||effect ||of ||agonist ||
(reduces ||baseline ||receptor ||activity)
Antagonist ||- ||CORRECT ||ANSWER✔✔-Binds ||receptor ||but ||blocks ||activation ||(no ||intrinsic ||
activity)
Inducers ||effect ||on ||drug ||levels ||- ||CORRECT ||ANSWER✔✔-↑ ||metabolism ||→ ||↓ ||drug ||level ||
→ ||↓ ||efficacy
, Inhibitors ||effect ||on ||drug ||levels ||- ||CORRECT ||ANSWER✔✔-↓ ||metabolism ||→ ||↑ ||drug ||level ||
→ ||↑ ||toxicity ||risk
Excitatory ||neurotransmitter ||(main) ||- ||CORRECT ||ANSWER✔✔-Glutamate
Inhibitory ||neurotransmitter ||(main) ||- ||CORRECT ||ANSWER✔✔-GABA
CYP ||interaction ||risk ||w/ ||fluoxetine ||+ ||inhibitor ||- ||CORRECT ||ANSWER✔✔-↑ ||SSRI ||levels ||→ ||
↑ ||serotonin ||syndrome ||risk ||(ex: ||ketoconazole)
Sample ||Q: ||Fluoxetine ||+ ||ketoconazole ||risk? ||- ||CORRECT ||ANSWER✔✔-CYP ||inhibitor ||
increases ||SSRI ||level ||→ ||↑ ||serotonin ||syndrome ||risk
MDD ||(DSM-5-TR) ||core ||criteria ||- ||CORRECT ||ANSWER✔✔-≥5 ||symptoms ||for ||≥2 ||weeks; ||one ||
must ||be ||depressed ||mood ||OR ||anhedonia
Persistent ||Depressive ||Disorder ||duration ||- ||CORRECT ||ANSWER✔✔-≥2 ||years ||of ||depressed ||
mood ||+ ||≥2 ||other ||symptoms
PMDD ||- ||CORRECT ||ANSWER✔✔-Diagnosed ||as ||Premenstrual ||Dysphoric ||Disorder
SSRIs ||first-line ||for ||- ||CORRECT ||ANSWER✔✔-MDD ||(and ||commonly ||anxiety ||disorders)
MAOI ||key ||safety ||issue ||- ||CORRECT ||ANSWER✔✔-Hypertensive ||crisis ||with ||tyramine-
containing ||foods
MAOI ||washout ||rule ||- ||CORRECT ||ANSWER✔✔-WaIt ||2 ||weeks ||before ||starting ||SSRIs ||after ||
MAOI ||(and ||vice ||versa ||per ||clinician ||plan)
